Table 1.

Baseline patient characteristics

ID	Diagnosis	Histology details	Age	Sex	Years with cancer	Previous lines of therapy
1	Colon cancer	Mucusal AC, KRASmut	65	F	6.3	2
2	Colon cancer	AC, KRASmut, MSI-low,	63	M	2.9	3
3	Colon cancer	AC, KRASmut, MSI-low	55	F	5.1	2
4	Colon cancer	AC, MSS	57	F	12.3	4
5	Colon cancer	AC, BRAFmut	44	M	1.2	2
6	Rectal cancer	AC, KRASmut, MSS	53	F	3.3	2
7	Rectal cancer	AC, MSS	45	M	2.4	4
8	CC	Chronic inflammation	66	F	3.9	2
9	CC	FGFR fusion	54	F	13.1	10*
10	CC	Klatskin	50	M	3	2*
11	Melanoma (skin)	PD-L1neg, BRAFwt	46	M	2.9	1†
12	Melanoma (skin)	PD-L1neg, BRAFmut	51	F	8.4	3†
13	Melanoma (choridea)	BRAFwt	47	F	4.9	2*
14	Melanoma (choridea)	BRAFwt	39	M	12.9	4*
15	Melanoma (choridea)		63	F	3.9	1*
16	Melanoma (choridea)	BRAFwt	55	M	1.2	2†
17	Leiomyosarcoma	Uterus-derived	48	F	2.9	3
18	Leiomyosarcoma	Liver-derived, grade 3	51	M	5.1	1
19	Oropharyngeal cancer (HNSCC)	SCC, P16+	57	M	5.3	2*
20	Cervix cancer	SCC, P16+, P40+	40	F	9.5	5*
21	Myoepithelial carcinoma	PD-L1neg	65	M	2.7	1
22	Adrenocorticocarcinoma	Weiss score 9	64	F	0.9	1
23	Non-small cell lung cancer	AC, PD-L1neg	45	F	6	4
24	Rhinopharyngeal cancer	Low diff.	43	F	4.5	2
25	Thyroid cancer	Low diff.	57	M	4.3	3
Median/ratio			53	11:14	4.3	2

Overview of all patients treated with adoptive cell therapy in the clinical trial.

*Included anti-PD-1/PD-L1.

†Included anti-PD-1 and anti-CTLA-4.

AC, adenocarcinoma; CC, cholangiocarcinoma; F, female; FGFR, fibroblast growth factor receptor; HNSCC, head-and-neck squamous cell carcinoma; M, male; MSI, microsatelite instability; MSS, microsatelite stability; SCC, squamous cell carcinoma.